	Under an agreement with LabCorp and Shandong XuanZhu Pharma, the wholly-owned subsidiary for  drug R&D of China-based Sihuan Pharmaceutical, Covance will support the preclinical and clinical development of the pharma's pipeline, which includes new molecules across a range of therapeutic areas, including cardiovascular, metabolic, infectious disease, oncology and urology. Specifically, Covance will provide Sihuan Pharmaceutical with global drug development and regulatory expertise, particularly in efforts to achieve dual or multiple filings for regulatory approvals such as investigational new drug (IND) applications and new drug applications (NDA) in China and internationally.  